$0.59
0.00 (-0.08%)
Open$0.59
Previous Close$0.59
Day High$0.59
Day Low$0.59
52W High$1.88
52W Low$0.53
Volume—
Avg Volume37.0K
Market Cap4.53M
P/E Ratio—
EPS$-0.49
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,640.5% upside
Current
$0.59
$0.59
Target
$10.33
$10.33
$6.34
$10.33 avg
$12.82
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.14M | 2.03M | 2.27M |
| Net Income | 217.1K | 264.7K | 291.2K |
| Profit Margin | 10.1% | 13.0% | 12.9% |
| EBITDA | 334.0K | 340.0K | 365.4K |
| Free Cash Flow | 225.5K | 170.6K | 157.9K |
| Rev Growth | +23.7% | +5.3% | -4.1% |
| Debt/Equity | 1.01 | 0.93 | 0.78 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |